Skip to main content

FDA recall, , High risk

MG217 Multi-Symptom Treatment Cream & Skin Protectant

MG217 Multi-Symptom Treatment Cream is contaminated with Staphylococcus aureus and could cause infections.

What happened

Wisconsin Pharmacal Company of Jackson, Wisconsin, recalled MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz (170 g), because of confirmed presence of Staphylococcus Aureus. The recall began on April 24, 2026, and was announced on May 8, 2026. The product was distributed nationwide in the USA and in the Bahamas.

The recalled product is manufactured by Pharmacal at 1 Pharmacal Way, P.O. Box 198, Jackson, WI 53037. The company recalled 690 tubes of the cream. The recall was added to the FDA's Enforcement Report on May 18, 2026, and was included in the FDA's weekly enforcement report on May 27, 2026. The FDA classified the recall on May 29, 2026.

2 photos

What to do

If a code on your package is listed below:

  1. Consumers that have product which is being recalled should stop using.
  2. Discard the product.
  3. Consumers with questions regarding this recall can contact Pharmacal by 800-558-6614 or email aimho@pharmacalway.com Monday through Friday from 8am -5pm central time.
  4. Contact your physician or healthcare provider if you have experienced any problems that may be related to using this product.

Is yours affected?

Match the UPC, lot code and expiration date listed under your product.

A UPC is the number printed under a barcode.

  1. MG217 Multi-Symptom Treatment Cream & Skin Protectant Eczema Cream

    UPC
    • 012277051067
    Lot code
    • 1024088
    Expiration date
    November 2026

Recall details

Company began the recall
Sold in

USA Nationwide and Bahamas

Company
Wisconsin Pharmacal CompanyJackson, Wisconsin
Risk

High risk

There is a reasonable chance that taking it could cause serious health problems or death.

FDA Class I recall · How risk is rated

Event ID
98788
Recall number
D-0553-2026
Quantity recalled
690 tubes

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Announced by the company

  3. Added to FDA's Enforcement Report

  4. Listed on Recall Canary

  5. In FDA's weekly enforcement report

  6. Classified by FDA

  7. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 7, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)